Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $21.24M
• Dividend Yield: N/A
• Average Volume (3M): 36.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 88.13%
• EPS Growth: 92.45%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 8,850,386
• 10 Day Avg. Volume: 51,818
• 30 Day Avg. Volume: 36,017
• PEG Ratio: 0.05
• Price to Book (P/B): 6.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.87
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 1.86
• Enterprise Value/Gross Profit: -0.62
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: $12.00
• Price Target Upside: 400.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: $2.00 ▼(-16.67%Downside)

Daré Bioscience's overall stock score is predominantly influenced by its financial instability, as reflected in the financial performance score. The company faces serious financial distress with negative equity and high liabilities. While there is potential upside from strategic initiatives and possible technical rebounds due to oversold conditions, these are overshadowed by financial and regulatory challenges.

Positive Factors

Funding

The recent grant from the Gates foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.

Market Strategy

The company's strategy to bring its sildenafil cream product to market through 503B-registered outsourcing is a smart move, as it will enable early market entry with a reliable product and raise patient awareness.

Partnership

Daré announced a partnership with Rosy Wellness, a women's health app recommended by over 8,000 healthcare professionals, to promote its sildenafil cream.

Negative Factors

Financial Performance

Daré reported a net loss of ($5.5M) for the full year, ending the period with $15.7M in cash on the balance sheet.

Regulatory Challenges

There is uncertainty around the regulatory pathway for the sildenafil cream, and the lack of statistical significance on most Ph2 endpoints raises concerns.

Regulatory Uncertainty

Sildenafil cream is intriguing but still needs FDA alignment, and there is uncertainty around the regulatory pathway.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative products for women's health. The company is based in San Diego, California, and it operates primarily in the healthcare and biotechnology sectors. Daré Bioscience's core products and services include a diverse pipeline of therapies aimed at addressing unmet needs in areas such as contraception, fertility, and menopause, with an emphasis on improving options and outcomes for women's reproductive health.

How the Company Makes Money

Daré Bioscience makes money primarily through strategic partnerships, licensing agreements, and potential future revenues from product sales pending regulatory approval and commercialization. The company enters into collaborations with larger pharmaceutical companies for the development and commercialization of its product candidates, which can provide revenue in the form of milestone payments and royalties on sales. Additionally, Daré may receive funding and grants from government bodies or non-profit organizations focused on advancing women's health. Given that Daré is still in the clinical-stage, it relies heavily on investment capital and partnerships to finance its operations and support the advancement of its product pipeline.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges with persistent unprofitability and high liabilities. Despite recent positive cash flow and revenue growth, negative equity and high operational costs indicate financial distress.

Income Statement

Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.

Balance Sheet

The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.

Cash Flow

While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.91K	9.78K	2.81M	10.00M	0.00	0.00
Gross Profit	-14.22M	-14.29M	2.77M	9.95M	-26.41K	-43.23K
EBITDA	-21.82M	-23.41M	-30.90M	-31.36M	-39.04M	-27.36M
Net Income	-1.68M	-4.05M	-30.16M	-30.95M	-38.33M	-27.40M
Balance Sheet
Total Assets	18.62M	22.10M	21.28M	43.83M	55.81M	7.55M
Cash, Cash Equivalents and Short-Term Investments	10.33M	15.70M	10.48M	34.67M	51.67M	4.67M
Total Debt	3.57M	1.30M	1.40M	488.74K	270.55K	756.84K
Total Liabilities	28.18M	28.11M	26.33M	32.71M	17.05M	8.70M
Stockholders Equity	-9.56M	-6.01B	-5.05M	11.11M	38.75M	-1.15M
Cash Flow
Free Cash Flow	-13.43M	4.82M	-39.49M	-18.15M	-28.78M	-25.25M
Operating Cash Flow	-12.99M	5.39M	-38.86M	-18.09M	-28.76M	-25.23M
Investing Cash Flow	-445.15K	-573.05K	-629.43K	-63.07K	-14.52K	-17.63K
Financing Cash Flow	572.72K	433.83K	15.64M	1.34M	75.85M	25.13M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Negative. The current price of 2.4 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 2.89, and below the 200-day MA of 3.16, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 30.75 is Neutral, neither overbought nor oversold. The STOCH value of 6.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	52 Neutral	$35.03M	―	-1738.36%	―	-43.55%	69.81%
VYNE	50 Neutral	$29.50M	―	-66.15%	―	43.03%	81.75%
Sector *	46 Neutral	C$194.85M	-4.28	-8.56%	2.84%	13.52%	-1.74%
GBIO	42 Neutral	$21.45M	―	-70.06%	―	146.47%	57.85%
PYPD	41 Neutral	$35.57M	―	-853.05%	―	―	34.97%
DARE	40 Underperform	$21.24M	―	597.53%	―	88.13%	92.45%
NRSN	30 Underperform	$45.58M	―	-2880.11%	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience Gains Nasdaq Compliance Extension Approval

On June 24, 2025, Daré Bioscience received approval from the Nasdaq Hearings Panel for its modified plan to regain compliance with Nasdaq Listing Rules, with a conditional continued listing period until August 12, 2025. The company must demonstrate compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule by July 31, 2025, or face potential delisting, which could impact its stock market presence and capital-raising capabilities.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience Announces Corporate Presentation for Investors

On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.